Effect of NMN Supplementation on Organ System Biology (VAN)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04571008|
Recruitment Status : Recruiting
First Posted : September 30, 2020
Last Update Posted : October 6, 2020
|Condition or disease||Intervention/treatment||Phase|
|Glucose Metabolism Disorders||Other: Placebo Dietary Supplement: Treatment||Not Applicable|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||56 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Primary Purpose:||Basic Science|
|Official Title:||Effect of Nicotinamide Mononucleotide (NMN) Supplementation on Organ System Biology|
|Actual Study Start Date :||October 1, 2020|
|Estimated Primary Completion Date :||September 2024|
|Estimated Study Completion Date :||September 2025|
Placebo Comparator: Placebo
At least 16 weeks of placebo.
Intervention will last at least 16 weeks in the form of two capsules.
Experimental: NMN supplementation
At least 16 weeks of NMN.
Dietary Supplement: Treatment
Intervention will last at least 16 weeks in the form of two NMN capsules (total of 300 mg/day).
- Change in Muscle insulin sensitivity [ Time Frame: before and after at least 16 weeks of treatment ]The outcome will be assessed during hyperinsulinemic-euglycemic clamp procedure in conjunction with stable isotopic tracer infusion before and after intervention period.
- Changes in glucose tolerance [ Time Frame: before and after at least 16 weeks of treatment ]The outcome will be assessed during modified oral glucose tolerance test
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04571008
|Contact: Ashley Robertsemail@example.com|
|Contact: Sally Torbitzkyfirstname.lastname@example.org|
|United States, Missouri|
|Washington University School of Medicine||Recruiting|
|Saint Louis, Missouri, United States, 63110|
|Contact: Sally Torbitzky, RN, BSN 314-362-8529 email@example.com|
|Principal Investigator: Samuel Klein, MD|
|Sub-Investigator: Mihoko Yoshino, MD PhD|
|Principal Investigator:||Samuel Klein, MD||Washington University School of Medicine|